Frontlight ResearchEarly access
Alzheimer disease trials, also abroad
902 open Alzheimer disease trials worldwide. Travel and costs are your own unless the study pays them; ask the study team first.
The same trial often runs in several countries
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) has 6 sites in India and runs in 31 countries. If a site near you is full, another one may still take people.
See Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) in all 31 countries